Showing results (241-250 of 336) with videos related to

Sort By:
Pageof 34
Carcinogenesis|January 23, 2010
Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese populationJi Young Park, Keitaro Matsuo, Takeshi Suzuki, et al.
Cancer Research Communications|November 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceKenichi Suda, Yukihiro Yoshida, Hidenori Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsTakamasa Koga, Kenichi Suda, Toshio Fujino, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 26, 2013
Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancerToshihiko Sato, Satoshi Teramukai, Haruhiko Kondo, et al.
Cancer Research|July 10, 2007
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1Hisaaki Tanaka, Kiyoshi Yanagisawa, Keiko Shinjo, et al.
Interactive Cardiovascular and Thoracic Surgery|August 21, 2016
Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancerYoshihisa Shimada, Kenji Suzuki, Morihito Okada, et al.
Translational Lung Cancer Research|July 23, 2021
Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic reviewZhe Zhang, Sen Yang, Yanfang Ma, et al.
JTO Clinical and Research Reports|May 16, 2022
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLCAkira Hamada, Kenichi Suda, Toshio Fujino, et al.
Lung Cancer (Amsterdam, Netherlands)|June 5, 2017
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cellsKenichi Suda, Leslie Rozeboom, Christopher J Rivard, et al.
JTO Clinical and Research Reports|March 18, 2026
Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in <i>EGFR</i>-Mutant Unresectable Stage III NSCLCShinkichi Takamori, Toshio Shimokawa, Atsushi Osoegawa, et al.
Pageof 34